ArticleJACC. Case reports2026
Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used for the management of diabetes and obesity. However, adverse effects beyond gastrointestinal symptoms remain incompletely characterized. CASE SUMMARY: A 73-year-old woman on long-term chlorthalidone for hypertension developed hyponatremia after initiation of tirzepatide 2.5 mg. Chlorthalidone was initially discontinued and later restarted at a reduced dose because of lower extremity edema. Serum sodium levels normalized and remained stable after escalation of tirzepatide to 7.5 mg. However, further escalation to 10 mg weekly was associated with recurrent symptomatic hyponatremia. Tirzepatide was subsequently discontinued, after which serum sodium levels normalized. Blood pressure remained within goal throughout these medication adjustments. DISCUSSION: This case highlights a temporal association between tirzepatide therapy and recurrent hyponatremia, possibly influenced by concomitant thiazide-like diuretic use. TAKE-HOME MESSAGE: Clinicians should consider monitoring serum sodium in patients receiving GLP-1 receptor agonists, particularly when used alongside medications affecting sodium balance, such as thiazide-like diuretic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.